Perspectives on the clinical development of immunotherapy in prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2018,（3）
• 页码范围: 253-259
• 页数: 7页
• 语种: 英文
• DOI: 10.4103/aja.aja_9_18

摘要

Despite impressive survival benefits with immunotherapy in patients with various solid tumors,the full potential of these agents in prostate cancer has yet to be realized.Sipuleucel-T demonstrated a survival benefit in this population,indicating that prostate cancer is an immunoresponsive disease;however,these results have not been matched by other agents.A large trial with ipilimumab in prostate cancer failed to meet its primary objective,and small trials with PD-1/PD-L1 inhibitors did not yield a significant improvement in overall response.However,several late-stage clinical trials are underway with other vaccines in prostate cancer.Reports of clinical benefit with immunotherapies,particularly when used in combination or a select population,have provided the framework to develop sound clinical trials.Understanding immunogenic modulation,antigen spread,biomarkers,and DNA-repair defects will also help mold future strategies.Through rational patient selection and evidence-based combination approaches,patients with prostate cancer may soon derive durable survival benefits with immunotherapies.